First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-Cisplatin
NCT00982111 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 633
Last updated 2022-01-11
Summary
The research study is testing the investigational drug necitumumab in the treatment of advanced non-small cell lung cancer. The aim of this study is to determine if necitumumab, given together with a standard chemotherapy combination consisting of cisplatin and pemetrexed will be more effective in improving participant disease than the standard chemotherapy combination alone.
Conditions
- Non Small Cell Lung Cancer
Interventions
- DRUG
-
Pemetrexed
500 milligram per square meter (mg/m2) administered Intravenously (I.V.) on Day 1 of every 3-week cycle, for a maximum of six cycles
- DRUG
-
75 mg/m2 administered I.V. on Day 1 of every 3-week cycle, for a maximum of six cycles
- BIOLOGICAL
-
Necitumumab
800 mg (absolute dose) on Days 1 and 8 of every 3-week cycle, administered as an I.V.
Sponsors & Collaborators
-
Quintiles, Inc.
collaborator INDUSTRY -
Parexel
collaborator INDUSTRY -
PPD Development, LP
collaborator INDUSTRY -
Medidata Solutions
collaborator INDUSTRY -
Laboratory Corporation of America
collaborator INDUSTRY -
University of Colorado, Denver
collaborator OTHER -
Thermo Fisher Scientific, Inc
collaborator INDUSTRY -
Pacific Biomarkers
collaborator OTHER -
Intertek
collaborator INDUSTRY -
Sysmex Inostics GmbH
collaborator INDUSTRY - lead INDUSTRY
Principal Investigators
-
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2009-11-02
- Primary Completion
- 2012-11-14
- Completion
- 2020-12-23
Countries
- United States
- Australia
- Austria
- Belgium
- Brazil
- Canada
- Croatia
- France
- Germany
- Greece
- Hungary
- Italy
- Poland
- Portugal
- Romania
- Russia
- Slovakia
- South Africa
- Spain
- United Kingdom
Study Locations
More Related Trials
-
Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
NCT00698815 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Pemetrexed and Cisplatin, in Non Small Cell Lung Cancer
NCT01000480 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Necitumumab in the First-Line Treatment of Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT01763788 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Chemotherapy for Patients With Non-Small Cell Lung Cancer Who Are Non-Smokers
NCT00409006 ·Status: COMPLETED ·Phase: PHASE2
-
A Study in Non-Small Cell Lung Cancer
NCT01232452 ·Status: COMPLETED ·Phase: PHASE2
-
Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer
NCT00686959 ·Status: COMPLETED ·Phase: PHASE3
-
Chemotherapy Treatment in Re-occurring Non Small Cell Lung Cancer (NSCLC) After Previous Chemotherapy and Surgical Removal of the NSCLC Tumor
NCT00356525 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of Induction and Maintenance Treatment of Advanced or Metastatic Non Squamous Non-Small Cell Lung Cancer
NCT00867009 ·Status: COMPLETED ·Phase: PHASE2
-
First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC
NCT00456261 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Cisplatin + Pemetrexed + Avastin as First-Line Therapy
NCT00998166 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of Necitumumab and Abemaciclib in Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT02411591 ·Status: COMPLETED ·Phase: PHASE1
-
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)
NCT02041533 ·Status: COMPLETED ·Phase: PHASE3
-
Carboplatin and Paclitaxel Combined With Cetuximab and/or IMC-A12 in Patients With Advanced Non-Small Cell Lung Cancer
NCT00986674 ·Status: COMPLETED ·Phase: PHASE2
-
Necitumumab in the Neoadjuvant Setting With Gemcitabine in Surgically Resectable - 14X-US-I001
NCT03574818 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of Induction and Maintenance Treatment of Advanced Non-squamous Non-Small Cell Lung Cancer
NCT00789373 ·Status: COMPLETED ·Phase: PHASE3
-
Chemotherapy for Patients With Non-Small Cell Lung Cancer (NSCLC)
NCT00391274 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer
NCT01471197 ·Status: TERMINATED ·Phase: PHASE2
-
Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer
NCT00095199 ·Status: COMPLETED ·Phase: PHASE3
-
Pemetrexed/Carboplatin Non-Small Cell Lung Cancer (NSCLC) Elderly Patients
NCT00350792 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer
NCT01519804 ·Status: COMPLETED ·Phase: PHASE2
-
Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy
NCT04253964 ·Status: RECRUITING ·Phase: PHASE2
-
An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
NCT02477826 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
NCT06946797 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)
NCT02657434 ·Status: COMPLETED ·Phase: PHASE3
-
Chemotherapy Combines With Bevacizumab and PD-1 Inhibitor in Non-squamous NSCLC
NCT05267366 ·Status: UNKNOWN ·Phase: PHASE2